Accutane (Isotretinoin) and Testosterone Interaction: What You Need to Know

Do isotretinoin and testosterone interact directly?

The Accutane label's drug interactions section lists vitamin A, tetracyclines, micro-dosed progesterone, norethindrone/ethinyl estradiol, St. John's wort, phenytoin and systemic corticosteroids [1]. It does not list testosterone. The Depo-Testosterone label's interactions section lists oral anticoagulants, oxyphenbutazone and insulin [2]. It does not list isotretinoin. Those lists are the clearest evidence on the direct interaction question.

What does isotretinoin do to triglycerides?

This is the best-documented side of the pair. The Accutane label reports serum triglyceride elevations above 800 mg/dL; marked triglyceride elevations occurred in about 25% of patients in clinical trials, about 15% developed a decrease in HDL, and about 7% had an increase in cholesterol [1]. The label says these lipid effects were reversible when isotretinoin stopped, and that some patients reversed triglyceride elevation with weight reduction, dietary fat and alcohol restriction, or dose reduction while continuing treatment [1].

The label says to check blood lipids before isotretinoin and then at intervals until the lipid response is established, which usually occurs within 4 weeks [1]. It flags extra care for patients with diabetes, obesity, increased alcohol intake, or a lipid metabolism disorder [1]. Acute pancreatitis has been reported in patients with either elevated or normal serum triglycerides, and in rare cases fatal hemorrhagic pancreatitis has been reported; the label says isotretinoin should be stopped if hypertriglyceridemia cannot be controlled at an acceptable level or if pancreatitis symptoms occur [1].

Does testosterone raise hematocrit?

The Depo-Testosterone label lists polycythemia as an adverse reaction [2]. The size of the effect depends on the product and route. A network meta-analysis of 29 placebo-controlled trials in 3,393 men found that intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% (95% CI 2.9 to 5.1) compared with placebo; gel raised it by 3.0% (95% CI 1.8 to 4.3), oral testosterone undecanoate by 4.3% (95% CI 0.7 to 8.0), patch by 1.4% (95% CI 0.2 to 2.6), and intramuscular testosterone undecanoate by 1.6% (95% CI 0.3 to 3.0) [3].

One retrospective review of 178 hypogonadal men followed for 3 years found erythrocytosis, defined as hematocrit above 50%, in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets [6]. That was not a randomized trial, and the injection group was younger (mean 42.5 years vs about 54 years) with a higher baseline hematocrit, so the percentages are not a clean head-to-head comparison [6].

The Accutane label lists decreases in red blood cell parameters among its hematologic effects, not erythrocytosis [1].

Does testosterone make isotretinoin less effective for acne?

Neither label says so. The isotretinoin label says clinical improvement in nodular acne occurs with a reduction in sebum secretion, reflecting a reduction in sebaceous gland size and inhibition of sebaceous gland differentiation [1]. The Depo-Testosterone label lists acne among the skin reactions that can occur with androgens [2]. That testosterone can cause acne does not by itself show that isotretinoin would work less well, and neither label addresses the question [1][2].

What about liver and psychiatric effects?

The Accutane label lists hepatitis and increases in liver enzymes (alkaline phosphatase, AST, ALT) among its adverse reactions [1]. The Absorica isotretinoin label calls for a fasting lipid profile and liver function tests before use. The Depo-Testosterone label warns that prolonged use of high doses of androgens, principally 17-alpha-alkyl androgens, has been associated with hepatic adenomas, hepatocellular carcinoma and peliosis hepatis [2].

The Accutane boxed warning is embryo-fetal toxicity and pregnancy contraindication, not psychiatric risk [1]. Depression, psychosis and rarely suicidal ideation, suicide attempts, and aggressive or violent behavior are in the Warnings section of the Accutane label [1]. The Depo-Testosterone label lists depression and anxiety among nervous system adverse reactions, and it says abuse of anabolic androgenic steroids can lead to serious psychiatric reactions, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression [2].

Does testosterone change iPLEDGE requirements?

The FDA pages tie iPLEDGE requirements to isotretinoin and to the patient's category (can or cannot get pregnant), not to other medicines [4][5]. The iPLEDGE REMS is a shared system for all FDA-approved isotretinoin products; prescribers and pharmacies must be registered and patients must be enrolled and meet the REMS requirements [4][5].

Patients who can get pregnant have pregnancy testing and prevention requirements. Patients who cannot get pregnant must still enroll [4][5].

FDA approved modifications to iPLEDGE on 9 February 2026. They include the option, if the prescriber permits, of at-home pregnancy tests during and after treatment (pre-treatment tests must still be done in a medical setting), no waiting period for a repeat test after a missed 7-day prescription window, and no monthly counseling documentation for patients who cannot get pregnant, who are counseled at enrollment [4][5]. FDA's page, current as of 16 June 2026, gives 15 November 2026 as the planned implementation date [4].

What should be monitored with both drugs?

The Accutane label's lipid schedule is before treatment and at intervals until the response is established, usually within 4 weeks [1]. The Depo-Testosterone label lists polycythemia as an adverse reaction and says to check hemoglobin and hematocrit periodically in long-term use [2]. The network meta-analysis supports the direction of the hematocrit effect: intramuscular enanthate or cypionate raised mean hematocrit by 4.0% versus placebo [3].